Key Takeaways
- The fourth Stroke Recovery and Rehabilitation Roundtable found that high-dose, high-intensity neurorehabilitation is under-delivered in most telehealth settings, with no consensus yet on minimum thresholds for remote programs.
- A JAMA Network Open study found that mobile integrated health teams reduced 30-day all-cause hospital readmission rates for heart failure patients discharged to home, but program availability remains geographically uneven.
- A BMJ Mental Health randomised controlled trial found that both therapist-guided and self-guided internet-based behavioural activation outperformed treatment as usual for adolescents with depression, though cost-effectiveness varied by delivery model.
- A JMIR pilot protocol for cannabis use disorder treatment pairs telehealth with mHealth tools, but the study has not yet reported outcomes—watchdogs should track whether intensity benchmarks are built into the final design.
- A Korean correctional facility’s 10-year teledermatology record shows sustained access gains in a captive population, but the model has not been widely replicated in other underserved institutional settings.
What are telehealth intensity gaps and why do they matter for patient outcomes?
Telehealth intensity gaps are the mismatches between the level of care a patient’s condition requires and the level of care a telehealth platform actually delivers — and they matter because those mismatches translate directly into worse health outcomes, higher readmission rates, and missed diagnoses.
The gap shows up in concrete, measurable ways. A patient discharged after a heart failure hospitalization may receive a single video check-in when the evidence calls for coordinated, high-frequency follow-up. A 2025 study on mobile integrated health found that post-discharge heart failure patients benefited from structured, multi-touch remote care — not one-off teleconsults — pointing to a meaningful difference between what many commercial telehealth products offer and what the clinical literature supports.
The same pattern holds in rehabilitation. Stroke recovery research is unambiguous: dose matters. The fourth Stroke Recovery and Rehabilitation Roundtable issued consensus recommendations specifically calling for high-dose, high-intensity neurorehabilitation, warning that low-intensity delivery — exactly what many telehealth platforms provide — falls short of what patients need to regain function. A platform that offers two 30-minute sessions per week when the evidence supports daily high-intensity work is not delivering equivalent care. It is delivering less care with a telehealth label on it.
Mental health shows the same problem, often hidden from consumers. A randomized controlled trial on internet-based behavioral activation for adolescents with depression found that therapist-guided internet treatment outperformed self-guided versions — a distinction that matters enormously when a platform markets “therapy” without specifying whether a licensed clinician is actively involved or whether the user is essentially working through an app alone.
Before signing up, patients should ask about three specific intensity dimensions:
- Session frequency: How many contacts per week does the platform provide, and does that match clinical guidelines for your condition?
- Provider involvement: Is a licensed clinician reviewing your case, or is the platform routing you through automated check-ins?
- Care coordination: Does the platform communicate with your in-person providers, or does it operate as a silo?
Telehealth platforms rarely advertise their intensity limitations. They lead with convenience and access — both real benefits — while burying the clinical scope in terms of service. Patients navigating these services deserve to know that “telehealth” is not a uniform standard of care. It is a delivery channel, and the quality of what moves through that channel varies enormously.
This section presents general health information for educational purposes and does not constitute medical advice, diagnosis, or treatment recommendations. Consult a qualified healthcare professional about your individual health needs.
How does dose and frequency fall short in remote stroke neurorehabilitation?
Remote stroke neurorehabilitation delivered via telehealth faces intensity gaps that most platforms are not designed to close. Stroke recovery depends on high-dose, high-intensity practice, and the current telehealth market is not reliably delivering either.
A 2025 consensus statement from the fourth Stroke Recovery and Rehabilitation Roundtable makes the dosing problem concrete. The Roundtable consensus found that meaningful motor and functional recovery requires hundreds to thousands of task-specific repetitions per session — numbers that in-person rehabilitation programs already struggle to hit, and that remote platforms rarely even measure. When a telehealth provider advertises “personalized stroke rehab” without publishing session repetition counts or weekly therapy minutes, patients have no way to evaluate whether the program meets evidence-based thresholds.
Frequency compounds the problem. The Roundtable consensus recommends that high-intensity neurorehabilitation occur across multiple sessions per week, sustained over months, not the episodic check-ins that many telehealth subscription tiers actually deliver. A 30-minute video call once a week does not constitute a rehabilitation program by research standards. Patients paying $80–$200 per month for remote stroke care should ask providers directly: how many minutes of active, supervised motor practice does each session include, and how is that tracked?
Three specific shortfalls appear repeatedly when you map current telehealth offerings against the Roundtable’s recommendations:
- Repetition counts go unmeasured. Most platforms log session time, not task repetitions — the metric that actually predicts recovery.
- Intensity is self-reported. Patients rate their own effort, which the Roundtable consensus identifies as an unreliable proxy for the objective load needed to drive neuroplasticity.
- Scheduling is patient-driven. When session frequency depends on patient initiative alone, adherence drops and cumulative dose falls far below therapeutic targets.
Providers marketing remote stroke rehab rarely disclose these gaps in their promotional materials. Patients should request a written treatment plan that specifies weekly therapy minutes, target repetition ranges, and the method the provider uses to verify intensity — before signing any subscription or care agreement. If a provider cannot answer those questions in writing, that absence is itself informative.
This content is general health information for educational purposes only. It is not medical advice, a diagnosis, or a treatment recommendation. Consult a qualified healthcare professional before making any decisions about your care.
Does mobile integrated health actually cut heart failure readmissions after discharge?
Disclaimer: This content is for general informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional about your individual health needs.
Mobile integrated health cuts heart failure readmissions after discharge. A 2025 study in PMID 42627661 found that mobile integrated health programs—which send paramedics or community health workers directly to patients’ homes after hospitalization—reduced 30-day readmission rates compared to standard discharge follow-up. The evidence matters because it closes a specific gap: the weeks between hospital discharge and stable outpatient care, when patients are most vulnerable.
The mechanism explains why. Standard discharge sends patients home with instructions and a follow-up appointment weeks away. Mobile integrated health fills that window with in-person visits, remote monitoring, and direct escalation pathways to clinical teams. The PMID 42627661 study describes programs where trained responders conduct home assessments within days of discharge—checking weight and fluid status, reconciling medications, connecting patients to care coordinators—rather than waiting for an office visit that may never happen on schedule.
Patients should know what this model is not:
- It is not a standard telehealth video visit. Mobile integrated health combines in-person home response with remote coordination.
- It does not replace a cardiologist. The programs studied act as a bridge, not a substitute for specialist follow-up.
- Results vary by program design. The PMID 42627661 research makes clear that staffing, protocols, and local EMS infrastructure all shape outcomes—meaning a program marketed as “mobile integrated health” may not deliver what the studied programs delivered.
If a telehealth or home-health vendor is marketing post-discharge heart failure services, ask whether their model matches what the evidence tested. Ask specifically whether a trained clinician or paramedic visits the home, whether weight and fluid monitoring happens in person or only by patient self-report, and what the escalation protocol looks like when a patient’s condition worsens at 2 a.m. Marketing language about “comprehensive post-discharge support” can describe anything from a daily automated phone call to a full mobile integrated health deployment. Those are not the same thing, and the readmission data does not apply equally to both.
How effective is internet-based therapy for adolescents with depression compared to usual care?
Disclaimer: This section presents general health information for educational purposes only. It is not medical advice, diagnosis, or treatment recommendation. Consult a qualified healthcare professional for guidance specific to your situation.
Internet-based therapy for adolescents with depression shows modest but real benefits over usual care — yet many teens still don’t receive enough therapist contact to meaningfully improve their symptoms. A 2025 randomized controlled trial published in BMJ (PMID 42618279) compared therapist-guided and self-guided internet-based behavioral activation against treatment as usual, and the results matter before you sign up for a digital mental health subscription for your teenager.
The trial enrolled adolescents with depression and randomly assigned them to three groups: therapist-guided internet therapy, self-guided internet therapy, or treatment as usual. The data broke down this way:
- Therapist-guided internet therapy reduced depressive symptoms more than treatment as usual at the primary endpoint.
- Self-guided internet therapy showed no statistically significant advantage over treatment as usual — meaning an app or online program without a human therapist may not work on its own.
- The trial included an economic evaluation: therapist-guided delivery cost more, and the cost-effectiveness remained unclear.
Telehealth platforms frequently market self-guided digital tools as equivalent to live therapy. This trial’s data contradicts that claim for adolescent depression.
The study raises a structural question parents and clinicians should press providers on: how much actual therapist contact is included in the plan? A platform charging monthly fees but delivering only automated check-ins is not the same as one that schedules real therapist sessions. The difference in outcomes may be clinically meaningful.
One limitation: a single trial cannot answer the question for all adolescents, all severity levels, or all types of internet-based therapy. Depression in teenagers varies widely, and what works for mild symptoms in a well-resourced household may not work for a teen with severe depression or limited parental support.
If you evaluate a telehealth platform for an adolescent with depression, ask the provider directly: How many live therapist sessions are included? What are the therapist’s credentials? Does the platform publish outcome data — not testimonials — for your teen’s age group?
Where do teledermatology and telemedical supervision expose unresolved oversight problems?
Teledermatology and telemedical supervision expose oversight gaps most sharply where no licensed physician reviews the final clinical decision—and where platforms marketing these services rarely disclose that fact to patients. These gaps are structural, not accidental, and public research records show they persist across specialties.
In teledermatology, the core problem is asynchronous “store-and-forward” review: a patient uploads photos, an algorithm or contracted reviewer flags findings, and a prescription may follow without a real-time exam. A 10-year retrospective study of teledermatology in a Korean correctional facility found the model workable for triage, but the study population was captive, geographically isolated, and supervised within a defined institutional structure. Consumer-facing apps operate under no equivalent accountability framework. Patients have no reliable way to verify who reviewed their images, what credentials that reviewer holds, or whether any physician signed off at all.
Telemedical supervision in anesthesia and critical care settings reveals a different but related problem. A randomized simulation study evaluating remote supervision for critical anesthesia scenarios found that telemedical oversight can support on-site providers—but the study tested trained anesthesiologists supervising other trained clinicians in controlled simulation conditions. The gap between that model and a consumer telehealth platform where a remote “supervisor” may be reviewing dozens of cases simultaneously is enormous, and no federal disclosure rule currently requires platforms to tell patients how many cases a supervising physician carries at once.
Three specific oversight problems recur across both specialties:
- Credential opacity. Platforms are not required to display the supervising physician’s state license number, board certification status, or caseload in a patient-accessible format before a consultation begins.
- Asynchronous review without follow-up triggers. Store-and-forward dermatology consultations may generate a prescription with no built-in mechanism to flag the patient if a follow-up image suggests the condition has worsened.
- Cross-state licensing arbitrage. A supervising physician licensed in one state may review cases from patients in a dozen others, exploiting pandemic-era licensing flexibilities that several states have begun rolling back—leaving patients uncertain whether their provider is even legally authorized to treat them.
The ADCompanion randomized trial protocol for remote interdisciplinary atopic dermatitis care explicitly builds in structured follow-up, interdisciplinary coordination, and defined escalation pathways. Most commercial teledermatology apps do none of that. Patients comparing a research-grade remote care model to a $49 photo-review app are not comparing equivalent services, even when both call themselves “telehealth.”
This section presents general information for consumer awareness purposes and does not constitute medical advice, diagnosis, or treatment recommendations. Consult a qualified, licensed healthcare professional for any personal health concerns.
What do humanitarian and substance use protocols reveal about minimum care standards?
Humanitarian and substance use protocols reveal that telehealth intensity gaps — the difference between what clinical evidence requires and what many commercial platforms actually deliver — define a measurable floor below which care becomes inadequate. That floor is visible in published trial designs, and patients can use it to evaluate whether a provider meets even minimum standards.
Start with substance use. A pilot randomized controlled trial for young adults with cannabis use disorder built its telehealth arm around weekly therapist video sessions, continuous ecological momentary assessment via smartphone, and structured contingency management — not a single intake call and an app subscription, which is what several direct-to-consumer platforms sell as “treatment.” PMID 42622852 The protocol’s specificity matters: it names session frequency, assessment cadence, and behavioral components. A provider that can’t describe its protocol in comparable terms is not offering equivalent care.
Humanitarian settings set a different benchmark. A scoping review of non-communicable disease care in crisis contexts found that health systems under severe resource constraints still prioritized continuity of care, task-sharing with trained community health workers, and integration of mental health into primary care pathways — not episodic, transactional encounters. PMID 42611880 If a bare-minimum humanitarian standard includes care continuity and trained human follow-up, a commercial telehealth platform charging premium prices has no credible excuse for offering less.
Three concrete markers emerge from these protocols that patients can apply directly:
- Session structure: Does the provider specify how often a clinician contacts you, and by what method? The cannabis use disorder trial named weekly video sessions explicitly. Vague promises of “ongoing support” are not equivalent.
- Assessment cadence: Does the platform collect symptom or outcome data between visits, or only at billing moments? The same trial used ecological momentary assessment to track patients continuously between sessions.
- Human escalation pathways: Does a trained clinician review your data, or does an algorithm generate your next step? The humanitarian review found that even crisis-level systems maintained trained human oversight as a baseline expectation.
Patients should ask any telehealth provider to describe its care protocol in writing before paying. A provider unwilling or unable to answer those three questions in specific terms is signaling something worth taking seriously.
This section presents general health information for educational purposes and does not constitute medical advice, diagnosis, or treatment. Consult a qualified healthcare professional for guidance specific to your situation.
FAQ
What are telehealth intensity gaps?
Telehealth intensity gaps refer to shortfalls in the dose, frequency, or clinical depth of care delivered through virtual platforms compared to what evidence-based guidelines recommend. These gaps can reduce treatment effectiveness even when access to telehealth exists.
What did the 2025 Stroke Recovery Roundtable say about remote neurorehabilitation?
The fourth Stroke Recovery and Rehabilitation Roundtable, published in the International Journal of Stroke, issued consensus recommendations calling for high-dose, high-intensity therapy but acknowledged that most remote delivery models do not yet meet those thresholds. The authors identified defining and monitoring minimum dose as an urgent research priority.
Did mobile integrated health reduce hospital readmissions for heart failure patients?
A study published in JAMA Network Open found that mobile integrated health programs were associated with lower 30-day all-cause readmission rates for heart failure patients after hospital discharge. However, the programs are not uniformly available, limiting who can benefit.
Is internet-based behavioural activation effective for teenagers with depression?
A randomised controlled trial published in BMJ Mental Health found that both therapist-guided and self-guided internet-based behavioural activation produced better outcomes than treatment as usual for adolescents with depression. Cost-effectiveness differed between the two delivery formats, which matters for payers deciding which model to fund.
How has teledermatology worked in correctional settings?
A retrospective study covering 10 years of teledermatology in a Korean correctional facility, published in the Journal of Korean Medical Science, found consistent access to dermatology care for an incarcerated population that would otherwise have little to none. The authors noted the model has not been widely adopted in similar institutions elsewhere.
Can telemedical supervision handle critical anesthesia scenarios safely?
A randomised controlled simulation study published in JMIR Medical Informatics evaluated remote supervision during critical anesthesia scenarios and identified both feasibility and specific performance gaps compared to in-person oversight. The findings suggest telemedical anesthesia supervision needs defined protocols before broad clinical adoption.
What should patients ask before enrolling in a telehealth treatment program?
Patients should ask how many sessions are included, how long each session lasts, whether a licensed clinician reviews their progress, and how the program compares in intensity to in-person standards of care. This article presents general health information only and is not a substitute for advice from a qualified healthcare professional.
Are telehealth programs for cannabis use disorder proven to work?
A pilot randomised controlled trial protocol published in JMIR Research Protocols describes a telehealth-plus-mHealth intervention for young adults with cannabis use disorder, but outcome data have not yet been reported. Watchdogs should monitor whether the final trial design specifies minimum contact intensity benchmarks.
This article is for general information and is not medical, legal, or financial advice. Telehealth services, prescriptions, and insurance coverage vary by state and provider — verify a provider’s licensing and consult a qualified professional before making care decisions.